Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say

Executive Summary

Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.
Advertisement

Related Content

Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees
Biosimilar User Fee Negotiations Under Way; Timetable Compressed
European Generics Need To Climb Into Niches, Huddle Together For Growth
Biosimilar Manufacturing Issues Should Be Focus Of User Fee Program, Firms Say
Biosimilar Manufacturing Issues Should Be Focus Of User Fee Program, Firms Say
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
Biosimilar User Fees Would Be Same As BLAs, Only Earlier
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
Generic User Fee Negotiations Begin In Ernest On Feb. 28 With Four Seats At The Table
FDA Searches For Clinical Trial Middle Ground At Biosimilar Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS053503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel